Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Point-of-care screening for sickle cell disease in low-resource settings: A multi-center evaluation of HemoTypeSC, a novel rapid test
source: American journal of hematology
year: 2019
authors: Steele C, Sinski A, Asibey J, Hardy-Dessources MD, Elana G, Brennan C, Odame I, Hoppe C, Geisberg M, Serrao E, Quinn CT
summary/abstract:Sickle cell disease (SCD) is a common, life-threatening genetic disorder that is best managed when diagnosed early by newborn screening. However, SCD is most prevalent in low-resource regions of the world where newborn screening is rare and diagnosis at the point-of-care is challenging. In many such regions, the majority of affected children die, undiagnosed, before the age of 5 years. A rapid and affordable point-of-care test for SCD is needed. The diagnostic accuracy of HemoTypeSC, a point-of-care immunoassay, for SCD was evaluated in individuals who had SCD, hemoglobin C disease, the related carrier (trait) states, or a normal hemoglobin phenotype. Children and adults participated in low-, medium- and high-resource environments (Ghana [n = 383], Martinique [n = 46], and USA [n = 158]).
Paired blood specimens were obtained for HemoTypeSC and a reference diagnostic assay. HemoTypeSC testing was performed at the site of blood collection, and the reference test was performed in a laboratory at each site. In 587 participants, across all study sites, HemoTypeSC had an overall sensitivity of 99.5% and specificity of 99.9% across all hemoglobin phenotypes. The test had 100% sensitivity and specificity for sickle cell anemia. Sensitivity and specificity for detection of normal and trait states were >99%. HemoTypeSC is an inexpensive (<$2 per test), accurate, and rapid point-of-care test that can be used in resource-limited regions with a high prevalence of SCD to provide timely diagnosis and support newborn screening programs.
organization: Operation International Kids, USA; Joseph M. Sanzari Children's Hospital, USA; Holy Family Hospital, Ghana; Hôpital Ricou, Guadeloupe; University Hospital of Martinique, France; University of Toronto, Canada; UCSF Benioff Children's Hospital Oakland, USA; Silver Lake Research Corporation, USA; Cincinnati Children's Hospital Medical Center, USADOI: 10.1002/ajh.25305
read more full text
Related Content
-
Inexpensive sickle cell diagnostic tool shows perfect accuracy in UgandaAn inexpensive, easy-to-use diagnostic t...
-
Blood Disorders That the Newborn Screen DetectsToday in the United States all newborns ...
-
Maternal/Perinatal Outcome in Women With Sickle Cell Disease: A Comparison of Two Time PeriodsObjective: To compare pregnancy outcome...
-
Study Suggests Ways of Improving Newborn Screening for Sickle Cell DiseaseResearchers in Spain have defined cutoff...
-
New Jersey may start a confidential sickle cell trait registryThe New Jersey Legislature is considerin...
-
Screening for sickle cell and beta thalassaemiaSickle cell and beta thalassaemi...
-
Sickle Cell Disease Association of America, Inc. Awards Community Based Organizations With $2,033,080 for Newborn Sc...The Sickle Cell Disease Association of A...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.